Pregy Capsule Uses

Pregy capsule belongs to the class of drugs known as anticonvulsants. It is primarily used to treat a variety of neurological and pain-related conditions that involve abnormal electrical activity in the brain or increased sensitivity of nerves. Following are some common uses of Pregy Capsule:

1. Neuropathic Pain: Pregy is commonly used for the treatment of neuropathic pain, which is pain caused by damage or dysfunction of the nerves. It can be used to manage various types of neuropathic pain, including diabetic neuropathy (nerve damage associated with diabetes), postherpetic neuralgia (nerve pain following shingles), and peripheral neuropathy (nerve damage in the peripheral nervous system).
2. Epilepsy: Pregy is used for the treatment of partial-onset seizures in adults with epilepsy. It is prescribed as an adjunctive therapy to other antiepileptic drugs to help control seizures.
3. Fibromyalgia: Pregy is also used for the management of fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain, fatigue, and tenderness. It can help reduce pain and improve overall function in individuals with fibromyalgia.
4. Generalized Anxiety Disorder: Pregy is used for the treatment of generalized anxiety disorder (GAD) in adults. It can help alleviate excessive worry, anxiety symptoms, and associated physical symptoms.

Off-label Uses of Pregy Capsule

1. Chronic Pain: Pregy may be used off-label for the management of chronic pain conditions, such as chronic low back pain, chronic pelvic pain, and neuropathic pain associated with conditions other than those specifically approved, such as nerve injury, multiple sclerosis, or chemotherapy-induced neuropathy.
2. Social Anxiety Disorders: Although Pregy is approved for generalized anxiety disorder (GAD), it may also be prescribed off-label for other anxiety disorders, such as social anxiety disorder (social phobia), panic disorder, and post-traumatic stress disorder (PTSD).
3. Insomnia: Pregy may be used off-label to help manage insomnia, particularly in individuals who experience significant anxiety or have neuropathic pain that contributes to their sleep difficulties.
4. Bipolar Disorder: Pregy may be used off-label as an adjunctive treatment for bipolar disorder, particularly in managing specific symptoms such as anxiety, sleep disturbances, or neuropathic pain associated with the condition.
5. Alcohol or Substance Withdrawal: Pregy may be prescribed off-label to help manage the symptoms of alcohol or substance withdrawal, such as anxiety, agitation, and sleep disturbances.
6. Restless Legs Syndrome: Pregy is sometimes used off-label for the treatment of restless legs syndrome (RLS), a neurological disorder characterized by an irresistible urge to move the legs, particularly during periods of rest or inactivity.

Pregy is one of the leading brands of Pregabalin, manufactured and marketed by Sami Pharmaceuticals (Pvt) Ltd, Pakistan.

Following are some alternative brands of Pregy and their manufacturers.

• Zeegap : Hilton Pharmaceuticals (Pvt) Ltd, Pakistan.
• Gabica : Getz Pharmaceuticals, Pakistan.
• Lyrica : Pfizer Laboratories Ltd.
• Pegalin : Shaigan Pharmaceuticals (Pvt) Ltd, Pakistan.
• Syngab : Atco Laboratories, Pakistan.
• Gablin : Consolidated Chemical Laboratories (CCL), Pakistan.
• Regab : Caraway Pharmaceuticals, Pakistan.
• Xaar : Wilshire Laboratories (Pvt) Ltd, Pakistan.
• Hilin : Highnoon Laboratories, Pakistan.
• Megab : Sante (Pvt) Ltd, Pakistan.
• Breglin : Brooks Pharmaceuticals, Pakistan.

Presently, Pregy is available in Capsule Forms with the following strengths.

Pregy Capsules : 25mg, 50mg, 75mg, 100mg, and 150mg strengths.

Pregy has certain contraindications, which are specific situations or conditions in which the use of Pregy is not recommended due to potential risks or adverse effects.

Hypersensitivity: Pregy should not be used in individuals who have a known hypersensitivity or allergy to Pregy or any of its components.

Angioedema: Pregy should be avoided in individuals with a history of angioedema (swelling of the face, lips, tongue, throat, or extremities) related to previous Pregy use.

Heart problems: Pregy should be used with caution in individuals with a history of heart problems, including heart failure. It may increase the risk of cardiovascular events such as heart rhythm abnormalities.

Kidney problems: Pregy is primarily eliminated from the body through the kidneys. Therefore, it should be used with caution and at lower doses in individuals with impaired kidney function or those on hemodialysis. Dose adjustments may be necessary.

Drug interactions: Pregy can interact with certain medications, such as opioids or central nervous system depressants. Combining Pregy with these substances may increase the risk of respiratory depression or central nervous system depression.

Pregnancy and breast-feeding: Pregy should only be used during pregnancy or breastfeeding if the potential benefits outweigh the potential risks. It is important to discuss the risks and benefits with a healthcare professional.

1. Pregy Dose for Neuropathic Pain:
   • Initial dose: One Capsule of 50mg two or three times a day.
   • Maintenance dose: One Capsule of 150mg two times a day, after 3-7 days if needed, based on individual response and tolerability.
2. Pregy Dose for Fibromyalgia:
   • Initial dose: One Capsule of 75mg per day, taken as a single dose.
   • Maintenance dose: One Capsule of 150mg three times a day, after 1 week if needed, based on individual response and tolerability.
3. Pregy Dose for Generalized Anxiety Disorder (GAD):
   • 2 to 4 Capsules of 150mg per day, divided into two doses.
   • The dose may be increased gradually over time, based on individual response and tolerability.
4. Pregy Dose for Epilepsy:
   • One capsule of 50mg, three times a day.
   • The dose may be increased to a maximum of 600 mg per day based on individual response and tolerability.

Pregy works by selectively binding to the alpha2-delta subunit of voltage-gated calcium channels in the brain and spinal cord. This binding reduces the calcium influx into nerve cells, leading to a decrease in the release of various neurotransmitters involved in the transmission of pain signals.